1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow GIST: new trials by email Literature Review of GIST trials Research Report on GIST
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) Nilotinib, Nilotinib with Imatinib - GIST, Metastatic Disease | Phase 2 | Terminated | Fox Chase Cancer Center | 5 | 2009-02-01 | 2017-03-15 |
Neoplasms (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Imatinib Mesylate (1) · nilotinib (1)
United States (1)